Overview
ProteoNic Biosciences provides premium vector and transposon technology, including the 2G UNic® platform, to boost protein production in mammalian, yeast, and fungal cells for biopharmaceutical manufacturing. Their solutions enhance expression of complex proteins like multi-specific antibodies, fusion proteins, and viral vectors, improving productivity and titers. The company supports biologics R&D and production, with recent licensing of 2G UNic® to Ginkgo Bioworks for BARDA-funded anti-filovirus therapies.
Frequently asked questions
- What vector technologies does ProteoNic offer for protein production?
- ProteoNic offers premium vector technology and the proprietary 2G UNic® transposon platform, which boost transcription, translation, and productivity for complex proteins in mammalian, yeast, and fungal cells.
- What applications are supported by ProteoNic's solutions?
- Their technology supports production of therapeutic proteins, multi-specific antibodies, fusion proteins, and viral vectors, including lentiviral vectors with enhanced gRNA and infectious particle titers.
- Where is ProteoNic based and how can I contact them?
- ProteoNic is based in Leiden, The Netherlands. Contact VP Business Development Jonathan Frampton at [email protected] or visit their FAQ page for more details.